Argenica Faces FDA Hold on US Stroke Trial Application

Argenica Therapeutics Ltd ( (AU:AGN) ) has shared an announcement.

Argenica Therapeutics has encountered a clinical hold from the US FDA on its Investigational New Drug application for an Acute Ischaemic Stroke trial, citing insufficient non-clinical data. This hold does not affect their ongoing Phase 2 trial in Australia, and the company is committed to addressing the FDA’s requirements to proceed with future US trials.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics to reduce brain tissue death following strokes and other neurological conditions. Their lead product, ARG-007, has shown promising results in pre-clinical models for stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. The company has completed a Phase 1 clinical trial and is currently conducting a Phase 2 trial in acute ischaemic stroke patients.

Average Trading Volume: 103,687

Technical Sentiment Signal: Buy

For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.